, BSc, ACGI, MBA, BSc, MBA, BEc, CA, BA, BA, LLL, JD, BSE, MA, MA, EdM, Solicitor, FCIS, FCS (PE), BSc, MBA, ACGI, MA, MBA, HonFCGI, BA, BMBCh, PhD, DM, DSc, FSB Panmure Gordon (UK) Limited Panmure Gordon (UK) Limited UBS Limited
1 1 2 3 5 8 31 33 38 47 48 49 50 52 54 55 112 *
2
3 106% 4,6002,240 3.906 3.453 65% 960 580 200 63% 590360 4,690 3,080 9,900 6,240 13% 3.9463.505 14% 3.43 2% 5,160 20% 1,8601,550 1099 51% 327% 2,950 690 2,220 730 5,480 1.036 240 280 Nutrition Science Partners LimitedNSP 880 NSP HMPL 004 NSP NSP
4 AstraZeneca AB (publ) c Met Volitinib(HMPL 504) 500 PRCC Fruquintinib(HMPL 013) VEGFR 8,650 15% HMPL 507 600 9,050 Sulfatinib Syk HMPL 523 2014 23% 1,2501,020 200 50 90
5 NSP HMPL-004 NATRUL-3 NATRUL-4 NATRUL-3 (HMPL-013) (HMPL-504) HMPL- 507 / HMPL-507 5,480 HMPL-523
6 14% 1,86020% 51% 20% 141 1,227 43% GMP 40 2,700 5.9 +106%
7 62.0 31.2 30.8 2013 1 1 36.9 5.0 (17.3) (2.5) 13.2 13.1 1.6 0.5 96.4 49.5 46.9 2013 12 31 11 ( NSP) 11 ( NSP) The Hain Celestial Group, Inc. (Nasdaq: HAIN)Hain Celestial 4,690 1,030 5,150 3,000 2,690 NSP 9,900 80 11 1,140
8 11 106% 4,600 2,240 327% 2,950690 23% 1,2501,020 25% 400 530 65% 960 580 200 620600 40 2 150120 Hain Celestial 110 10
9 (1) 18.6 (+20%) 29.5 (+327%) (2.4) (-187%) 12.5 (+23%) (0.5) (+45%) (1) 394.6 (+13%) 110100 5% 63% 590360 11.4 7.0 51% 13% 3.946 3.505 14% 3.4303.001 GSP 5,5605,570 20% 1,8601,550 (i) ( 601607) 50%(ii) ( 600332) 50% (iii) 600 (1) 2013 394.6 2012 350.5 2011 271.0 2013 2012 2011 14.0 15.5 18.6
10 (1) 394.6 ( +13% ) 123.6 (+21%) 74.2 (+13%) 71.9 (+20%) 16.3 (+0%) 12.4 (+6%) 10.1 (+46%) 3.4 (-23%) 82.7 (-1%) (1)
11 ( ) 19% (2000-2005) 5.9 6.9 7.7 9.4 10.3 31% (2005-2012) 200 80% 14.1 16.3 25.5 40.0 58.7 72.0 92.6 122.7 00 02 04 06 08 10 12 51% 20% 10% 1,227 31% 4.6%5.4% 16% 11% 2020 6.5% - 7.0% 6.4%
12 () 22% (2006-2012) 401 (30%) 317 (24%) 223 (17%) 160 (12%) 432 (32%) 473 (35%) 536 (40%) 8,608 31 278 06 07 08 09 10 11 12 2011 5.364.73 160 8.05 6.4 70 7%14% 11% 12% 46% 1,760 43% 1,58043% 23.1% 21.3% 1) 2) 3) 4) 5)
13 > 1,000 500 1,000 100 490 < 100 1.382 19% 1.165 10% 2% 88%
14 19% 1.382 1.165 25% 73 32 32 17 15 99.7% 14 3 13.4% 13.1% 19% 12% 65 7% 4% 21% 1.236 1.022 20 10 39% 11% 6,260 5,620 25% 7,5506,030 55% 38% 1,500 6% 1,240 1,160
15 > 1,000 500 1,000 100 490 < 100 2.525 10% 2.287 29% 1% 4% 7% 30% 29%
16 1,600 1,500 13,000 10,000 24,000 54% GMP 13 78,000 40 GMP 147 69 62 3435 87% 28 9 GSP 70.2% 67.9% 80% 7% 13% 7,420 6,540 5 35 H1N1 8 10% 2.5252.287 13% 2.008 1.783 GSP 2% 5,160 5,050 2013
17 20% 7,1906,020 24% 24% 4% 4,5004,9004,700 7,000 50 80010,000 6,500 20,000 390 50% GMP 9 23 40 66,000 GMP
18 200 18% 980 51% 49% 5,000 100 2,990 2,700 25% 400530 300% 60 20 DHA omega-3
19 86,100 59,400 1 26,700 2 2 1 2 12 2 800 1 2 2.37 530 12 8,000 58,000
20 Hutchison MediPharma Holdings Limited 2 HMPL 004 HMPL 507 NSP50% 7,200 4.76 1.45 5.6 HMPL 004 (Sulfatinib, HMPL 012) Epitinib(HMPL 813) Theliatinib(HMPL 309)
21 HMPL-004 HMPL-004 (HMPL-013) (HMPL-012) (HMPL-813) (HMPL-309) (HMPL-504) Syk (HMPL-523) FGFR (HMPL-453) (HMPL-507) 20 84 33% 1% 7% 6% 20 24% 327% 2,950690 NSP 240 280 NSP 880NSP 1,750 NSP 1,700 450 200 5,480 230
22 NATRUL 3 NATRUL 4 NSP 3,010 1,310 VEGF 8,650 650 15% / HMPL 507 600 9,050 500 NSP 12.2% 1,250 NSP 12.2% (i) HMPL 523 HMPL 453 HMPL 507 (ii) (iii) HMPL 004 NSP
23 HMPL 004 NSP HMPL 004 80 (5 ASA) 5- COX LO PPARγ HMPL-004 ~70% 40-60% ~70% HMPL 004 2,000~7,000 15,000~20,000 HMPL 004 HMPL 004 HMPL 004 HMPL 004 24 NATRUL 4 HMPL 004 1,80052 NATRUL 3 NATRUL 4 HMPL 004 NSP NSP NATRUL 3 HMPL 0041,800 2,4008 (5 ASA) 6513 NATRUL 3 HMPL 0042,700
24 EGFR VEGFRc Met Syk FGFR PI3K (HMPL 504) c Met c Met c Met c Met c-met 30 PRCC PRCC 10 15% PRCC c Met c Met PRCC c Met PRCC PRCC c Met
25 VEGF/VEGFR VEGF VEGF VEGF/VEGFR Sorafenib Nexavar TM Sunitinib Sutent 10 12 Bevacizumab, Avastin TM 61 VEGF/VEGFR (HMPL 013) VEGF VEGFR1 VEGFR2 VEGFR3 VEGFR 30% (ORR) 38%4/ 46% 18% 2% 40 5 / 4 / 58 GMP
26 (HMPL 012) (VEGFR) VEGFR FGFR VEGFR FGFR I 57 EGFR EGFR EGFR EGFR EGFR EGFR EGFR EGFR 10 30%EGFR
27 Tarceva TM Iressa 14 6 Erbitux 18 EGFR (1) EGFR (2) EGFR (3) EGFR T790M (n=13) EGFR (HMPL 813) EGFR EGFR 30 40% EGFR EGFR 8 10% 50% EGFR 28 240 EGFR EGFR EGFR
28 (Theliatinib, HMPL 309) EGFR EGFR EGFR EGFR EGFR EGFR EGFR 14 60 I EGFR EGFR B B Rituximab Rituxan TM MabThera TM Syk B B Syk Fostamatinib GS 9973Gilead Sciences HMPL 523 Fostamatinib Fostamatinib HMPL 523 GLP HMPL 523 I HMPL 523 Syk HMPL 453 (FGFR) HMPL 507 HMPL 507 600 HMPL-523 - HMPL 523 HMPL 523 Syk SykB HMPL 523 1 2 MPK = / QD = BID = QOD = PO = IP = Naïve = Fostamatinib SYK R406
29 23% 1,250 1,020 200 140 60Hain Celestial 50 90 Hain Celestial Sen Sen 39%, 2,870 4%, 290 (Euromonitor) Avalon Organics Earth s Best Imagine Terra Walnut Acres Organic Health Valley 45 Hain Celestial 23% 1,020 830 16% 670 31% 230 24%, 1,810 1%, 80 32%, 2,420 51% 110 15% 640 63% 91% 170
30 HMPL-004 NATRUL-3 Syk HMPL-523
31 1 2 3 62 48 47 Hutchison MediPharma (Hong Kong) Limited Sen Medicine Company Limited 3 7 4 5 1 2 9 6 8
32 4 5 79 Hutchison Whampoa Japan K.K. 40 64 Hutchison Whampoa Luxembourg Holdings S.à r.l. (ITU) GSMA Limited Asia Task Force 6 7 62 66 Transport Initiatives Edinburgh Ltd. FPT Group Limited Railtrack Group plc 8 9 62 300 Biological Reviews, the Journal of Physiology and Europace (B.A.) (B.M., B.Ch.) (Ph.D.) (D.M.) (D.Sc.) (FSB) 55 NTR plc GKN Evo edrive Systems Ltd Gasrec Limited Current OpenGrid Limited Global Crossing Ltd. North West Water International Ltd. S.G. Warburg and Co. Ltd.
33 48 52 53 14 18 22
34 91(1) 31 32 320,000 192,108 153,600 26,506 20,000 2,475 (i)
35 19.5.2006 (1) 768,182 768,182 19.5.2006 3.6.2015 1.090 25.8.2008 (3) 64,038 64,038 25.8.2008 24.8.2018 1.260 19.5.2006 (1) 76,818 76,818 19.5.2006 3.6.2015 1.090 11.9.2006 (2) 26,808 26,808 11.9.2006 18.5.2016 1.715 18.5.2007 (4) 43,857 (3,000) 40,857 18.5.2007 17.5.2017 1.535 28.6.2010 (3) 102,628 102,628 28.6.2010 27.6.2020 3.195 1.12.2010 (3) 227,600 (50,000) 177,600 1.12.2010 30.11.2020 4.967 24.6.2011 (3) 150,000 150,000 24.6.2011 23.6.2021 4.405 20.12.2013 (3) 896,386 896,386 20.12.2013 19.12.2023 6.100 1,459,931 896,386 (3,000) (50,000) 2,303,317 (1) AIM 50% 25% (2) (3) 25% (4) (ii) Hutchison MediPharma Holdings Limited ( )
36 6.8.2008 (1) 1,243,000 (1,186,000) 57,000 6.8.2008 5.8.2014 1.28 5.10.2009 (1) 234,000 (184,000) 50,000 5.10.2009 4.10.2015 1.52 3.5.2010 (1) 360,000 (60,000) 300,000 3.5.2010 2.5.2016 2.12 2.8.2010 (1) 206,000 (181,000) 25,000 2.8.2010 1.8.2016 2.24 22.11.2010 (1) 240,000 (240,000) 22.11.2010 21.11.2016 2.36 18.4.2011 (1) 562,385 (455,965) 106,420 18.4.2011 17.4.2017 2.36 17.10.2012 (1) 299,120 (299,120) 17.10.2012 16.10.2018 2.73 3,144,505 (2,606,085) (2) 538,420 (1) 25% (2) 2,606,085(i) 2,485,189 / (ii) 120,896 3% Hutchison Healthcare Holdings Limited (1) ( HHHL ) 36,666,667 70.44% Computershare Company Nominees Limited (2) ( CCNL ) 15,295,025 29.38% CCNL Chase Nominees Limited 2,768,865 5.32% Slater Investments Limited (3) 3,170,000 6.09% (3) 2,640,514 5.07% (1) HHHLHHHL (2) CCNL SC167175 (3)
37 4th Floor, Hutchison House, 5 Hester Road, Battersea, London SW11 4AN
38 AIM 31 32 (www.chi-med.com)
39 100% 4/4 4/4 4/4 4/4 4/4 4/4 4/4 4/4 4/4
40 AIMAIM AIM AIM 47
41 100% 4/4 4/4 4/4
42
43
44 AIM 100%
45 20,128 (1) (4) 20,128 337,974 (2) (4) 602,564 14,423 22,846 (5) 977,807 262,016 (2) 203,846 20,266 (5) 486,128 20,128 (3) 20,128 20,128 (1) 20,128 20,128 (3) (4) 20,128 53,138 53,138 53,138 53,138 53,138 53,138 839,916 806,410 14,423 43,112 1,703,861 (1) (2) 20,128 (3) (4) (5)
46 100% Investor Relations 4th Floor, Hutchison House, 5 Hester Road, Battersea, London 100% info@chi-med.com
47 48 111
48 5 45,970 22,367 (22,208) (12,754) 23,762 9,613 (3,452) (5,694) (21,295) (21,376) 6 (a) 1,603 1,871 6 (b) 11,476 17 10,937 17,147 7 11,555 13,037 8 (1,485) (1,160) 10,070 11,877 9 (1,050) (1,116) 9,020 10,761 10 (1,978) (7,221) 7,042 3,540-7,323 9,472 - (1,408) (5,834) 5,915 3,638 23 1,127 (98) 7,042 3,540-11(a) 0.1407 0.1824-11(b) 0.1385 0.1799-11(a) 0.1136 0.0701-11(b) 0.1119 0.0691
49 7,042 3,540 3,342 662 10,384 4,202-10,360 10,616 - (1,503) (6,248) 8,857 4,368 1,527 (166) 10,384 4,202
50 14 5,028 3,344 4,550 15 1,508 1,498 1,523 16 407 407 407 14,166 17 111,405 109,552 66,690 18 285 280 390 118,633 115,081 87,726 19 1,420 1,590 4,327 20 13,410 9,508 12,168 3,356 1,583 2,221 30 1,985 1,194 5,676 21 46,863 30,767 42,525 67,034 44,642 66,917 185,667 159,723 154,643 22 52,051 52,048 51,743 36,819 18,530 13,042 88,870 70,578 64,785 23 15,966 11,620 11,324 104,836 82,198 76,109
51 24 4,163 3,183 4,941 25 15,389 15,229 11,912 30 7,374 6,303 5,345 26 51,508 10,892 29,731 158 78,434 35,607 52,087 4,551 18 2,397 2,528 1,758 27 12,467 20,138 26 26,923 2,397 41,918 26,447 80,831 77,525 78,534 (11,400) 9,035 14,830 107,233 124,116 102,556 185,667 159,723 154,643
52 51,743 92,955 4,748 8,650 496 (93,807) 64,785 12,545 77,330 2 (1,221) (1,221) 51,743 92,955 4,748 8,650 496 (93,807) 64,785 11,324 76,109 3,638 3,638 (98) 3,540-224 224 224-506 506 (68) 438 730 730 (68) 662 730 3,638 4,368 (166) 4,202 22(a) 305 714 (390) 629 629 796 796 796 (180) 180 30(b) 1,000 1,000 30(a) (538) (538) 52,048 93,669 4,974 9,380 496 (89,989) 70,578 11,620 82,198
53 52,048 93,669 4,974 9,380 496 (89,989) 70,578 13,070 83,648 2 (1,450) (1,450) 52,048 93,669 4,974 9,380 496 (89,989) 70,578 11,620 82,198 5,915 5,915 1,127 7,042-662 662 62 724-2,280 2,280 338 2,618 2,942 2,942 400 3,342 2,942 5,915 8,857 1,527 10,384 22(a) 3 6 (2) 7 7 332 332 25 357 (168) 168 27 (120) (243) 9,459 9,096 3,371 12,467 30(a) (577) (577) 52,051 93,675 5,016 12,079 496 (74,447) 88,870 15,966 104,836
54 28 (4,065) (18,123) 451 388 (1,485) (1,160) (1,181) (393) 11,308 7,837 5,028 (11,451) (2,500) (430) (4,169) 11 (2,500) (4,588) 1,516 (577) (538) 1,000 26,923 14,261 (568) (18,839) 7 629 27 (6,519) 13,123 4,172 15,651 (11,867) 30,767 42,525 445 109 46,863 30,767 21 46,863 30,767
55 1 10 22 P.O. Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands AIM 2 IFRS 11,400,000 26,923,000 IASB IAS 1IFRS 11 IFRS 12 (A) IAS 1 (B) IFRS 11
56 2 IFRS 11 (i) i) ii) iii) iv) v) (ii) IAS 28 IFRS 11
57 2 (195,977) 100,400 (95,577) 57,070 24,978 (1,231) 10,937 (3,823) 21 (3,802) 3,802
58 2 (24,440) (16,405) (8,059) (15,144) (36) 111,405 (1,756) 45,565 (31,162) (32,168) (6,526) 1,896 (49,578) (117,538) (71,973) (1,700) (1,700) (20,797) (43,585) (1,378) (410) (66,170) (3,861) (242) (4,103) (70,273) (51,368) (5,803) (71,973)
59 2 195,531 (173,164) 22,367 (98,135) 85,381 (12,754) 97,396 (87,783) 9,613 (60,595) 54,901 (5,694) (34,747) 13,371 (21,376) 2,602 (731) 1,871 11,476 11,476 17,147 17,147 16,132 (3,095) 13,037 (1,209) 49 (1,160) 14,923 (3,046) 11,877 (4,162) 3,046 (1,116) 10,761 10,761 (7,221) (7,221) 3,540 3,540 662 662 4,202 4,202 10
60 2 22,848 (19,504) 3,344 23,277 (18,727) 4,550 10,440 (8,942) 1,498 6,175 (4,652) 1,523 8,311 (7,904) 407 8,248 (7,841) 407 15,585 (15,585) 14,858 (692) 14,166 32 (32) 31 (31) 109,552 109,552 66,690 66,690 1,639 (1,359) 280 1,550 (1,160) 390 58,855 56,226 115,081 54,139 33,587 87,726 25,318 (23,728) 1,590 28,720 (24,393) 4,327 44,343 (34,835) 9,508 51,573 (39,405) 12,168 3,940 (2,357) 1,583 5,063 (2,842) 2,221 15,000 (13,806) 1,194 1,516 4,160 5,676 62,009 (31,242) 30,767 53,763 (11,238) 42,525 150,610 (105,968) 44,642 140,635 (73,718) 66,917 209,465 (49,742) 159,723 194,774 (40,131) 154,643
61 2 52,048 52,048 51,743 51,743 18,530 18,530 13,042 13,042 70,578 70,578 64,785 64,785 13,070 (1,450) 11,620 12,545 (1,221) 11,324 83,648 (1,450) 82,198 77,330 (1,221) 76,109 18,897 (15,714) 3,183 16,451 (11,510) 4,941 43,715 (28,486) 15,229 35,568 (23,656) 11,912 6,303 6,303 5,345 5,345 11,202 (310) 10,892 30,038 (307) 29,731 951 (951) 1,074 (916) 158 81,068 (45,461) 35,607 88,476 (36,389) 52,087 2,692 (2,692) 6,919 (2,368) 4,551 2,667 (139) 2,528 1,911 (153) 1,758 12,467 12,467 20,138 20,138 26,923 26,923 44,749 (2,831) 41,918 28,968 (2,521) 26,447 125,817 (48,292) 77,525 117,444 (38,910) 78,534 69,542 (60,507) 9,035 52,159 (37,329) 14,830 128,397 (4,281) 124,116 106,298 (3,742) 102,556 209,465 (49,742) 159,723 194,774 (40,131) 154,643
62 2 (C) IFRS 12 IFRS 12 17 23 (a) 2(d) (b) 2(d) (c)
63 2 (d) (e)
64 2 (f) 2(I) (g) 2(f) (h)
65 2 (i) (j) (k) (l)
66 2 (m) (n) (o) (p) (q) (r)
67 2 (s) (t) (i) (ii) i)ii) iii) (u) (v) (w)
68 2 (x) (y) (i) (ii) (iii) (iv) (v) (z)
69 2 IAS 19 (2) IAS 32 (1) IAS 36 (1) IAS 39 (1) IFRS 10 IFRS 12 IAS 27 (1) IFRS 9 (4) IFRS 14 (3) 21 (1) (2) (2) (1) (2) (3) (4) 3 (a) (i)
70 3 (a) (ii) (iii) 21 26 100 509,000 316,000
71 3 (a) (iv) 26 27 535,000 448,000 11,400,000 26,923,000 (b) 26 51,508 37,815 88,870 70,578 58.0% 53.6%
72 3 (c) 4 2 (a) (b)
73 4 (c) 16 2(l) (d) (e) (f) (g) (i) (ii) (i) (ii) 6(b) IFRS 3 NSP IFRS 3
74 5 16,470 15,452 29,500 6,915 45,970 22,367 (40) 38 166 45,930 22,571 252,220460 730 230 EBIT/(LBIT) 10
75 5 3,985 29,500 923 11,562 45,970 45,970 EBIT/(LBIT) 806 6,495 (80) (486) 6,735 (6,568) 167 9 31 12 2 54 397 451 19,702 (8,765) 10,937 10,937 20,517 (2,239) (68) (484) 17,726 (6,171) 11,555 186 186 1,299 1,485 5 2,461 2 2,468 32 2,500 16 889 3 15 923 40 963 97,271 50,272 1,768 8,312 157,623 27,113 184,736
76 5 1 (41) (40) (40) LBIT (1,141) (837) (1,978) (1,978) (1,141) (837) (1,978) (1,978) 283 648 931 931
77 5 5,277 6,915 787 9,388 22,367 22,367 EBIT/(LBIT) 432 2,624 (400) (901) 1,755 (6,253) (4,498) 8 153 3 1 165 223 388 17,132 15 17,147 17,147 17,572 2,792 (397) (900) 19,067 (6,030) 13,037 171 171 989 1,160 4,518 4 6 4,528 114 4,642 30 1,392 1 18 1,441 25 1,466 87,933 45,608 2,137 7,631 143,309 14,483 157,792
78 5 (783) 344 643 204 204 LBIT (3,273) (3,201) (747) (7,221) (7,221) (3,273) (3,201) (747) (7,221) (7,221) 1 1 1 35 1 36 36 363 1,568 1,931 1,931 414,000 628,000 485,000 EBIT EBIT 6,735 1,755 (6,568) (6,253) 451 388 10,937 17,147 (1,485) (1,160) 10,070 11,877 6,823,0005,104,0001,000 120,000144,000
79 6 (a) 451 388 1,217 308 4 35 (69) (12) 27 1,152 1,603 1,871 6 (b) Hutchison MediPharma (Hong Kong) Limited Nestlé S.A. Nutrition Science Partners LimitedNSP NSP 4(g)NSP 50% NSP18,524,000 NSP NSP NSP 7 408 376 38 36 16,823 9,072 925 1,430 41 22 88 42 17 78 672 556 4,475 5,894 13 16,517 14,675 88,000 41,00022,000
80 8 922 689 30 471 471 30 92 1,485 1,160 9-1,186 236 18 (136) 880 1,050 1,116 (a) (b) 15% 25%
81 9 (c) 10,070 11,877 5,115 1,750 (4,453) (5,044) 817 3,774 (1,677) 1,029 1,005 219 (369) 1,050 1,116 50.8%14.7% 10.4%9.4%
82 10 1 2 (31) 896 (1,947) (8,117) (1,978) (7,221) (1,978) (7,221) (1,239) (893) 4 1,026 (1,239) 137 1 (40) 38 166 9 692 (31) 896 2 7 1,349 36 239 1,728 1 106 198 712 96 1,446 927 72 840 1,202
83 11 (a) 52,050,988 51,918,898-7,323 9,472 - (1,408) (5,834) 5,915 3,638-0.1407 0.1824 - (0.0271) (0.1123) 0.1136 0.0701 (b) 52,050,988 51,918,898 827,438 731,464 52,878,426 52,650,362-7,323 9,472 - (1,408) (5,834) 5,915 3,638 0.1385 0.1799 0.1119 0.0691
84 11 (b) 12 280 276 1,381 1,301 43 41 10 1,704 1,628 13 12,953 10,818 1,793 1,547 1,414 1,558 357 752 16,517 14,675 5,256,0002,418,000
85 14 22,955 4,218 13,061 14,415 860 55,509 (20,483) (1,751) (12,983) (5,356) (860) (41,433) 2,472 2,467 78 9,059 14,076 79 79 3 299 18 478 55 4 1,211 1,230 2,500 (18) (148) (166) 2,551 2,583 85 10,421 1,248 16,888 9,916 3,778 8,141 10,826 32,661 (9,291) (1,476) (8,081) (3,081) (21,929) 625 2,302 60 7,745 10,732 21 73 2 255 351 115 19 13 778 925 (17) (131) (148) 761 2,377 75 8,647 11,860 1,790 206 10 1,774 1,248 5,028
86 14 21,479 5,293 12,014 14,229 1,967 54,982 (19,027) (1,313) (11,931) (4,399) (1,936) (38,606) 2,452 3,980 83 9,830 31 16,376 20 34 1 81 136 50 377 3 430 (1,597) (6) (1,229) (34) (2,866) 2,472 2,467 78 9,059 14,076 8,774 5,032 7,619 10,280 31,705 (8,266) (1,343) (7,583) (2,687) (19,879) 508 3,689 36 7,593 11,826 5 33 1 72 111 112 121 23 1,210 1,466 (1,541) (1,130) (2,671) 625 2,302 60 7,745 10,732 1,847 165 18 1,314 3,344
87 15 1,706 1,692 55 14 1,761 1,706 208 169 7 3 38 36 253 208 1,508 1,498 16 407 407 11% 11% 5%
88 17 61,883 50,479 49,522 59,073 111,405 109,552 40% (i) 50% Nutrition Science Partners Limited 43.88% (ii) NSP (i) 50% 20% (ii) NSP 50% 12.24%
89 17 (i) NSP 51,587 38,121 30,331 24,196 17,031 94,110 85,740 44,828 35,925 30 30,000 145,697 123,861 75,159 60,121 17,061 30,000 59,446 39,848 35,646 30,203 30,000 30,000 (620) (820) (91,760) (63,472) (38,484) (29,113) (4,604) (91,760) (64,092) (39,304) (29,113) (4,604) (3,180) (3,809) (5,025) (1,853) 110,203 95,808 66,476 59,358 42,457 60,000
90 17 (ii) NSP 252,465 228,728 138,160 116,544 (3,598) (2,671) (2,612) (2,411) 1,103 227 197 151 (44) (41) (58) 20,386 19,420 26,620 20,931 (17,543) (3,408) (2,823) (4,196) (3,267) 16,978 16,597 22,424 17,664 (17,543) 3,879 898 848 434 20,857 17,495 23,272 18,098 (17,543) 6,462 6,256 16,154 3,110 15,00032,000 24,00035,000
91 17 (iii) NSP 95,808 84,569 59,358 44,370 60,000 60,000 16,978 16,597 22,424 17,664 (17,543) (6,462) (6,256) (16,154) (3,110) 3,879 898 848 434 110,203 95,808 66,476 59,358 42,457 60,000 50% 55,102 47,904 33,238 29,679 21,229 30,000 3,282 3,180 (1,700) (1,450) 53,402 46,454 36,520 32,859 21,229 30,000 254,000239,000 1,329 750 8,379 278
92 18 285 280 (2,397) (2,528) (2,112) (2,248) (2,248) (1,368) 136 (769) (111) (2,112) (2,248) 22,384,000 24,124,000 68,206 64,385 10,590 8,437 9,323 10,829 686 350 16,470 10,281 1,272 95,957 104,872
93 19 483 488 937 1,102 1,420 1,590 20 10,424 6,757 30 2,986 2,751 13,410 9,508 1,554 1,470 42 72 74 12 1,670 1,554 1,670,0001,554,000
94 20 3,703,0004,797,000 1,136 846 959 916 1,608 3,035 3,703 4,797 21 20,946 13,948 (a) 25,917 16,819 46,863 30,767 12,203 4,163 (b) 32,139 22,678 212 311 1,651 2,231 658 1,384 46,863 30,767 (a) 7 90 2.1% 2.7% (b)
95 22 (a) 1 75,000,000 75,000 51,743,153 51,743 305,295 305 52,048,448 52,048 52,048,448 52,048 3,000 3 52,051,448 52,051 1 51,212 192,108 53,650 8,325 3,000 1.090 1.260 1.715 1.535 1.535 86 377 145 21 7 3.68 3.98 3.83 3.83 4.40
96 22 (b) (i) 4.4% (i) AIM 1.090 768,182 (iii) 1.260 64,038 (i) AIM 1.090 76,818 (ii) 1.715 26,808 (iv) 1.535 40,857 (iii) 3.195 102,628 (iii) 4.967 177,600 (iii) 4.405 150,000 (iii) 6.100 896,386 2,303,317
97 22 (b) (i) 2.22 1,459,931 2.06 1,765,226 6.10 896,386 1.54 (3,000) 1.32 (305,295) 4.97 (50,000) 3.67 2,303,317 2.22 1,459,931 (i) AIM 50% 25% (ii) (iii) 25% (iv) (v) 2,303,317 882,000 1,444,000 (iii) 206,000416,000
98 22 (b) (i) 1.546 0.553 0.533 0.569 1.361 1.995 1.841 3.154 1.090 1.715 1.535 1.260 3.195 4.967 4.405 6.100 2.5050 1.7325 1.5400 1.2600 3.1500 4.6000 4.3250 6.100 (i (v) 38.8% 38.8% 40.0% 35.0% 49.9% 48.43% 46.6% 36.00% 4.540% 4.766% 5.098% 4.700% 3.340% 3.360% 3.130% 3.160% 1.2 3.9 3.4 5.3 3.9 5.7 7.1 8.0 6.25 6.25 6.25 6.25 0% 0% 0% 0% 0% 0% 0% 0% (i) (ii) (iii) (iv) (v)
99 22 (b) (ii) Hutchison MediPharma Holdings Limited 1.8% 25% (i) 1.28 57,000 (i) 1.52 50,000 (i) 2.12 300,000 (i) 2.24 25,000 (i) 2.36 106,420 538,420
100 22 (b) (ii) 1.87 3,144,505 1.73 4,050,607 2.73 299,120 (ii) 1.80 (2,606,085) 1.61 (1,205,222) 2.03 538,420 1.87 3,144,505 (i) 25% (ii) 2,606,085(i) 2,485,189 (ii) 120,896 (iii) 538,420 79,000 (i) 151,000336,00044,000
101 22 (b) (ii) 0.034 0.027 0.361 0.258 0.923 1.280 1.520 2.120 2.240 2.360 0.270 0.261 1.098 1.030 2.048 53% 53% 54% 49% 55% 3.293% 2.564% 2.772% 2.007% 2.439% 4.6 5.8 6 6 6 6 0% 0% 0% 0% 0%
102 23 15,966,00011,620,000 10,587,000 9,260,000 Hutchison BYS (Guangzhou) Holding Limited3,626,000 1,753,0002,360,000 20% (i) 12.24% (ii) 50% (i) 5 4 (ii) 172 8 21,215 14,468 8,230 7,944 53,335 46,387 28,104 35,122 45 64 (1,060) (879) (19,928) (18,640) (4,734) (3,300) (3,265) (2,980) (12,466) (9,600) (9,600) 49,182 42,536 29,391 18,484 (6,059) (4,892)
103 23 29,500 6,915 10,157 8,290 8,286 8,076 (2,238) 2,791 (1,215) (3,977) (446) (503) (21) 7,840 7,573 (2,259) 2,791 (1,215) (3,977) 1,352 288 295 150 48 (398) 9,192 7,861 (1,964) 2,941 (1,167) (4,375) 577 538 1,141,0003,277,000 163 2,903 (136) (2,457) 3,982 163 4,428 (136) 8 8,227 4,609 314 52 171 12,969 4,525 30
104 24 1,811 1,508 30 2,352 1,675 4,163 3,183 25 5,327 2,893 3,047 1,263 3,895 4,728 12,269 8,884 248 11 2,872 1,783 4,551 3,120 6,345 15,389 15,229 2,000 460460
105 26 (i) 26,923 (i) (ii) 51,508 10,892 51,508 37,815 1.67% 1.87% (i) 26,923,000 (ii) (a) 51,508 10,892 26,923 51,508 37,815
106 26 (b) 48,718 37,179 2,790 636 51,508 37,815 27 2.725 7,390,029 2,010 7672,815,249652 115 6(a) 1,2474,574,780 100%87.76%
107 28 7,042 3,540 1,050 1,116 357 752 38 36 137 1,468 88 927 42 72 925 1,466 18 184 (11,476) (1,152) (451) (388) (10,937) (17,147) 1,485 1,160 493 (27) 287 (19,469) - (55) 342 - (3,944) 2,588 - (1,773) 638 - (89) - (614) (188) - (88) - 980 (1,758) - 160 3,317 - (4,551) - 1,157 958 - (86) (4,065) (18,123) - - (2,826) (17,230) (1,239) (893) (4,065) (18,123)
108 29 (a) 459 (b) 748 523 1,654 1,067 486 623 2,888 2,213
109 30 (a) 7,803 6,967 3,612 6,304 4,802 4 569 591 914 914 92 471 471 577 538 12 26
110 30 (b) 20 (i) 2,986 2,751 24 (i) 2,352 1,675 (i) 88 (i) 89 (i) 1,808 1,194 1,985 1,194 (iii) 7,374 6,217 (i) 86 7,374 6,303 (ii) 5,379 5,379 (i) (ii) (iii) 31 Hutchison Healthcare Holdings Limited 32 48 111
111 33 100% 100% 207,460,000 37,500,000 87.76% 100% 1,000,000 50% 50% 1 100% 100% 3,000,000 50% 50% 50% 50% 229,000,000 Nutrition Science 20,000 43.88% 50% Partners Limited 40% 40% 200,000,000
112 AIM HCM P.O. Box 309, Ugland House Grand Cayman, KY1-1104 Cayman Islands +1 345 949 8066 +1 345 949 8080 Computershare Investor Services PLC The Pavilions Bridgwater Road Bristol BS99 6ZY United Kingdom +44 (0)906 999 0000 +44 (0)870 703 6114 10 22 +852 2128 1778 ediths@hwl.com.hk 10 22 +852 2128 1188 +852 2128 1778 10 21 +852 2121 8200 +852 2121 8281 ir@chi-med.com +852 2121 8200 +852 2121 8281 www.chi-med.com Computershare Investor Services (Jersey) Limited Queensway House Hilgrove Street, St. Helier Jersey, Channel Islands JE1 1ES +44 (0)870 707 4040 +44 (0)870 873 5851 (a) (b)